Baseline clinical characteristics of heart failure patients with reduced ejection fraction enrolled in the BUDAPEST-CRT Upgrade trial

The BUDAPEST-CRT Upgrade study is the first prospective, randomized, multicentre clinical trial investigating the outcomes after cardiac resynchronization therapy (CRT) upgrade in heart failure (HF) patients with intermittent or permanent right ventricular pacing (RVP) with wide paced QRS. This repo...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Merkely Béla
Gellér László
Zima Endre
Osztheimer István
Molnár Levente
Földesi Csaba
Duray Gábor
Németh Marianna
Goscinska-Bis Kinga
Sághy László
Veres Boglárka
Fábián Alexandra
Fodor Eszter
Kovács Attila
Kosztin Annamária
Dokumentumtípus: Cikk
Megjelent: 2022
Sorozat:EUROPEAN JOURNAL OF HEART FAILURE 24 No. 9
Tárgyszavak:
doi:10.1002/ejhf.2609

mtmt:32925440
Online Access:http://publicatio.bibl.u-szeged.hu/24693
Leíró adatok
Tartalmi kivonat:The BUDAPEST-CRT Upgrade study is the first prospective, randomized, multicentre clinical trial investigating the outcomes after cardiac resynchronization therapy (CRT) upgrade in heart failure (HF) patients with intermittent or permanent right ventricular pacing (RVP) with wide paced QRS. This report describes the baseline clinical characteristics of the enrolled patients and compares them to cohorts from previous milestone CRT studies.This international multicentre randomized controlled trial investigates 360 patients having a pacemaker (PM) or implantable cardioverter defibrillator (ICD) device for at least six months prior to enrollment, reduced left ventricular ejection fraction (LVEF≤35%), HF symptoms (New York Heart Association functional class II-IVa), wide paced QRS (>150 ms), and ≥20% of RVP burden without having a native left bundle branch block. At enrollment, the mean age of the patients was 73±8 years; 89% were male, 97% of the patients were in NYHA II/III functional class, and 56% had atrial fibrillation. Enrolled patients predominantly had conventional PM devices, with a mean RVP burden of 86%. Thus, this is a patient cohort with advanced HF, low baseline LVEF (25%±7%), high N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels [2231 pg/mL (25th - 75th percentile 1254/4309 pg/mL)], and frequent HF hospitalizations during the preceding 12 months (50%).When compared with prior CRT trial cohorts, the BUDAPEST-CRT Upgrade study includes older patients with a strong male predominance and a high burden of atrial fibrillation and other comorbidities. Moreover, this cohort represents an advanced HF population with low LVEFs, high NT-proBNPs, and frequent previous HF events.
Terjedelem/Fizikai jellemzők:1652-1661
ISSN:1388-9842